https://openbell.ai/ 2026-11-02T21:51:48.624Z hourly 1.0 https://openbell.ai/support 2026-11-02T21:51:48.624Z monthly 0.7 https://openbell.ai/privacy 2026-11-02T21:51:48.624Z monthly 0.5 https://openbell.ai/terms 2026-11-02T21:51:48.624Z monthly 0.5 https://openbell.ai/feed.json 2026-11-02T21:51:48.624Z hourly 0.8 https://openbell.ai/news/O:1793655132000 2026-11-02T21:32:12.000Z daily 0.9 https://cdn.brandfetch.io/O/w/400/h/400?c=1idopYfmtR7ZKg8QMud Realty Income Corporation Reports Q3 2026 Operating Results and Raises AFFO Guidance Realty Income reported Q3 2026 net income of $403.9 million, or $0.43 per share, while AFFO rose 3.7% year over year to $1.12 per share. The company invested $2.6 billion at an initial weighted average cash yield of 6.8% and raised its 2026 AFFO guidance to $4.45–$4.46 per share, reaffirming its $10.0 billion annual investment target. Realty Income reported a 103.5% rent recapture rate on re-leased properties and said it is expanding its private capital platform into Europe through a joint venture with KKR. https://openbell.ai/news/FANG:1793655119000 2026-11-02T21:31:59.000Z daily 0.9 https://cdn.brandfetch.io/FANG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Diamondback Energy Reports Third Quarter 2026 Financial and Operating Results Diamondback Energy reported third-quarter 2026 revenue of $5.43 billion and adjusted earnings per share of $5.86, both above analyst estimates. It generated $2.6 billion in operating cash flow and $2.1 billion in free cash flow. The company raised its annual base dividend 7.3% to $4.72 per share and increased annual oil production guidance to approximately 524 MBO/d. Diamondback also repurchased 1.3 million shares for $251 million and acquired a 7.5% interest in the Solitude Pipeline System, a Permian-to-Katy natural gas pipeline. https://openbell.ai/news/PLTR:1793655119000 2026-11-02T21:31:59.000Z daily 0.9 https://cdn.brandfetch.io/PLTR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Palantir Technologies Inc. Reports Q3 2026 Financial Results Palantir Technologies reported Q3 2026 revenue of $2.31 billion, above the $2.18 billion FactSet consensus, and adjusted EPS of $0.44, topping the $0.41 estimate. U.S. commercial revenue reached $984 million, exceeding U.S. government revenue of $953 million for the first time. Citing strong demand for its AI software, the company raised its 2026 revenue guidance to $8.530 billion–$8.534 billion. https://openbell.ai/news/GILD:1793655118000 2026-11-02T21:31:58.000Z daily 0.9 https://cdn.brandfetch.io/GILD/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Approves Long-Acting HIV Prevention Drug The FDA approved Gilead Sciences’ long-acting injectable lenacapavir for HIV prevention. Administered twice yearly, it offers an alternative to daily PrEP pills and may help address adherence challenges and stigma. The article reports no financial figures or stock-price impact. https://openbell.ai/news/BSX:1793655114000 2026-11-02T21:31:54.000Z daily 0.9 https://cdn.brandfetch.io/BSX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Boston Scientific Announces Positive Results from SIMPLAAFY Clinical Trial Boston Scientific reported positive results from the SIMPLAAFY trial, which randomized 1,857 patients at 86 U.S. sites after WATCHMAN FLX Pro implantation. Aspirin alone and reduced-dose NOAC alone were noninferior to dual anti-platelet therapy (DAPT), with less bleeding and equivalent ischemic stroke rates. At 45 days, reduced-dose NOAC was also associated with fewer device-related thrombi than DAPT. The findings support simpler post-implant treatment for patients with non-valvular atrial fibrillation. https://openbell.ai/news/PG:1793655106000 2026-11-02T21:31:46.000Z daily 0.9 https://cdn.brandfetch.io/PG/w/400/h/400?c=1idopYfmtR7ZKg8QMud P&G Increases Cost Pressure Forecast and Plans Price Hikes Procter & Gamble raised its forecast for the earnings impact of higher raw material, energy and freight costs to $1.4 billion, up from $1 billion. CFO Andre Schulten said the company plans to increase prices to help offset the inflationary pressures affecting its global operations. https://openbell.ai/news/VRTX:1793655100000 2026-11-02T21:31:40.000Z daily 0.9 https://cdn.brandfetch.io/VRTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Vertex Pharmaceuticals Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance Vertex Pharmaceuticals reported third-quarter 2026 revenue of $3.44 billion, up 12% year over year, driven by its cystic fibrosis franchise and contributions from CASGEVY, JOURNAVX, and PALSONIFY. The company raised its full-year revenue guidance to $13.15 billion–$13.25 billion. Vertex also said it completed its acquisition of Crinetics Pharmaceuticals and is preparing for a potential regulatory milestone for povetacicept in renal medicine later in November. https://openbell.ai/news/EQIX:1793649714000 2026-11-02T20:01:54.000Z daily 0.9 https://cdn.brandfetch.io/EQIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Equinix Reports Strong Q3 Results, Raises 2026 Guidance, and Announces $700 Million Stock Offering Equinix reported Q3 revenue of $2.57 billion, up 11% year over year, and net income of $489 million, up 31%. The company raised its 2026 revenue and AFFO-per-share guidance for the third consecutive quarter and projected 2026 cabinet deliveries nearly 40% above prior forecasts, with 3 GW of developable capacity. Equinix filed for a $700 million common stock offering and a shelf registration statement, and agreed to fund electrical grid infrastructure for a Georgia project. https://openbell.ai/news/PFE:1793649712000 2026-11-02T20:01:52.000Z daily 0.9 https://cdn.brandfetch.io/PFE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Pfizer Reports Q2 Revenue Growth and Raises Full-Year Outlook Pfizer reported second-quarter revenue growth of 18% year over year, excluding currency impacts. The company raised the midpoint of its full-year revenue forecast by $500 million. Pfizer is scheduled to release its complete quarterly financial results later this week. https://openbell.ai/news/INDV:1793646189000 2026-11-02T19:03:09.000Z daily 0.9 https://cdn.brandfetch.io/INDV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Supernus Pharmaceuticals Completes Merger With Indivior Pharmaceuticals Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, combining their operations and resources to create a more diversified company focused on central nervous system biopharmaceuticals. The combined company plans to use its broader portfolio of marketed medicines and increased financial flexibility to strengthen its market position and support long-term growth. The article reports no financial terms or stock-price impact. https://openbell.ai/news/RAMP:1793646180000 2026-11-02T19:03:00.000Z daily 0.9 https://cdn.brandfetch.io/RAMP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Publicis Groupe Completes Acquisition of LiveRamp Publicis Groupe completed its acquisition of LiveRamp, previously valued at approximately $2.2 billion. The deal is intended to combine LiveRamp’s data collaboration and privacy expertise with Publicis’s broader capabilities to build a plug-and-play AI growth engine for clients. Publicis said LiveRamp will retain its existing identity, culture and neutrality; the transaction was financed with available cash and debt. https://openbell.ai/news/INDB:1793646167000 2026-11-02T19:02:47.000Z daily 0.9 https://cdn.brandfetch.io/INDB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Independent Bank Corp. Reports Third Quarter 2026 Results and Acquisition Completion Independent Bank Corp. reported adjusted third-quarter 2026 EPS of $0.80, down from $0.84 a year earlier. Net interest income increased, supported by growth in productive assets and expanded margins. The company completed its acquisition of HCB Financial Corp. during the quarter, and integration of the Highpoint Community Bank system is underway, with completion expected by November 9, 2026. https://openbell.ai/news/JOBY:1793646156000 2026-11-02T19:02:36.000Z daily 0.9 https://cdn.brandfetch.io/JOBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Joby Aviation Reports Quarterly Results and Raises 2026 Revenue Outlook Joby Aviation reported quarterly revenue above analyst expectations but posted a wider-than-expected loss. It raised its 2026 revenue outlook to $115 million–$125 million. The company said five aircraft are flying and 12 are in production as it advances through the final stage of FAA certification, and launched a week-long Florida air-taxi flight series with the state’s transportation department, including a planned demonstration across Tampa Bay.